Stocks on Trader’s Radar: Deutsche Bank AG (USA) (NYSE:DB), Duke Energy Corp (NYSE:DUK), Ionis Pharmaceuticals Inc (NASDAQ:IONS)

On Thursday, Shares of  Deutsche Bank AG (USA)(NYSE:DB), subtract -0.44% and closed at $13.53 in the last trading session. The last trading range of the stock ranges between $13.27 and $13.68. Deutsche Asset Administration’s (Deutsche AM) Alternatives business recently declared the acquisition of a 19-property, 3.3 million square foot industrial portfolio from International Airport Centers (IAC). The properties are located in seven major distribution markets across the US – Los Angeles, San Francisco, Seattle, Dallas, Chicago, Portland and San Diego.

The portfolio, which consists of 35 buildings, is 99% leased to 76 tenants with an average tenant size of about 40,000 square feet. Deutsche AM attained the portfolio on behalf of an institutional shareholder through direct negotiation with IAC’s investment advisor – Perlmutter Investment Company.

“The portfolio’s geographic diversity across large distribution hubs and stable tenant base makes it an attractive investment,” said Todd Henderson, Head of Alternatives – Real Estate, Americas. “We are excited about the acquisition of such a diverse portfolio of industrial real estate and “appreciate the opportunity to work with IAC on this transaction.”

Duke Energy Corp (NYSE:DUK), REMAIN FLAT  and closed at $77.09 in the last trading session. The last trading range of the stock ranges between $76.54 and $77.90. The company’s Market capitalization is $52.86 Billion with the total Outstanding Shares of 688.93 Million. — As Hurricane Matthew approaches the east coast of Florida, officials there are telling residents there will be power outages.

The storm, which has restrengthened to Category 4, with winds reaching around 140 miles per hour, continues to track toward the Carolinas and is expected to arrive Saturday.

Thousands of Duke Energy personnel are being mobilized and are ready to respond.

“We’ve stocked our trucks and warehouses, accomplished our readiness plans based on Matthew’s projected path, and coordinated with local, state and national emergency personnel to ensure we have the most optimized response,” said Bobby Simpson, Duke Energy’s Carolinas storm director. “You can’t beat the forces of nature, but we will do everything we can to restore power as quickly and safely as possible.”

Ionis Pharmaceuticals Inc (NASDAQ:IONS), lost -5.83% and closed at $34.26 in the last trading session. The last trading range of the stock ranges between $33.12 and $36.30. During the 52-week trading session the minimum price at which share price traded, registered at $19.59 and reached to max level of $65.64. Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, develops drugs for patients with severe and rare diseases in the United States. The company markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia, and Alicaforsen for ulcerative colitis and pouchitis. Its drugs in Phase III development include Nusinersen for the treatment of patients with spinal muscular atrophy; IONIS-TTRRx for the treatment of patients with various forms of TTR amyloidosis, counting familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; Custirsen to treat cancer; and Plazomicin for the treatment of severe bacterial infection. The company’s products under development also include IONIS-DMPK-2.5 for myotonic dystrophy type 1; IONIS-HTT for huntington’s disease; ATL1103 for acromegaly; IONIS-SOD1 for amyotrophic lateral sclerosis; IONIS-FXI (BAY 2306001) for clotting disorders; IONIS-APO(a)-L for high Lp; IONIS-ANGPTL3-L for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5 (AZD9150) for cancer; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; RG-101 for hepatitis C virus infection; IONIS-GCGR and IONIS-PTP1B for type 2 diabetes; and IONIS-FGFR4 for obesity. In addition, it is developing IONIS-GCCR for cushing’s syndrome; IONIS-PKK for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5 (AZD5312) for prostate cancer; IONIS-GSK4-L for ocular disease; IONIS-HBV and IONIS-HBV-L for hepatitis B virus infection; and IONIS-DGAT2 for nonalcoholic steatohepatitis.

Leave a Reply

Your email address will not be published. Required fields are marked *